ライフサイエンスコーパス: cotrimoxazole

1 ed, by household, to continue or discontinue cotrimoxazole.

2 n or to ceftiaxone, and 13 were resistant to cotrimoxazole.

3 tinuing (n = 452) vs discontinuing (n = 384) cotrimoxazole, 0.4 vs 12.2%, respectively, had at least

4 = -2 (adjusted odds ratio, 1.70 vs not using cotrimoxazole [95% confidence interval, 1.28-2.25], P <

5 By univariate analysis, cotrimoxazole and antiretroviral therapy conferred risk

6 >25% became significantly different between cotrimoxazole and non-cotrimoxazole users after 6 months

7 The adjusted mean change in HAZ among cotrimoxazole and non-cotrimoxazole users did not differ

8 on of P. carinii pneumonia prophylaxis (with cotrimoxazole and pentamidine).

9 Effectiveness of cotrimoxazole (CTX) compared with sulfadoxine-pyrimetham

10 Cotrimoxazole (CTX) discontinuation increases malaria in

11 Cotrimoxazole (CTX) prophylaxis is recommended by the Wo

12 The growth benefits of cotrimoxazole during early antiretroviral therapy (ART)

13 Antenatal provision of cotrimoxazole for HIV-infected pregnant women with low C

14 Cotrimoxazole has antimalarial effects and appears to re

15 monia programs in developing countries where cotrimoxazole is widely used.

16 Antimicrobial prophylaxis consisted of cotrimoxazole, itraconazole, and aciclovir (or valgancic

17 cocci and carriage of PCV7-type pneumococci, cotrimoxazole-nonsusceptible (COT-NS) pneumococci, or pe

18 ated children, the proportion colonized with cotrimoxazole-nonsusceptible pneumococci increased from

19 ated children, the proportion colonized with cotrimoxazole-nonsusceptible pneumococci increased from

20 , unless the patients were prescribed 480 mg cotrimoxazole once daily.

21 old treated with sulfadoxine/pyrimethamine, cotrimoxazole, or no antimicrobial agent were enrolled i

22 Compared to those remaining on cotrimoxazole, patients who discontinued had a relative

23 Cotrimoxazole preventive therapy (CPT) is recommended fo

24 indicated in HIV-infected women taking daily cotrimoxazole prophylaxis (CTXp) because of potential ad

25 We investigated whether antenatal cotrimoxazole prophylaxis begun during pregnancy for HIV

26 is required in HIV-positive women not using cotrimoxazole prophylaxis for opportunistic infections.

27 -Saharan Africa and who abruptly discontinue cotrimoxazole prophylaxis have an increased incidence of

28 Cotrimoxazole prophylaxis is recommended for subgroups o

29 Cotrimoxazole prophylaxis prolongs survival and prevents

30 Cotrimoxazole prophylaxis was associated with higher pla

31 Cotrimoxazole prophylaxis was introduced as a routine co

32 confidence interval {CI}, 0.24-0.98]) after cotrimoxazole prophylaxis was introduced than before; th

33 ed with development of nocardiosis; low-dose cotrimoxazole prophylaxis was not found to prevent nocar

34 egnant women on antiretroviral treatment and cotrimoxazole prophylaxis.

35 late ART, loss to follow-up, and absence of cotrimoxazole prophylaxis.

36 ite, maternal education, economic level, and cotrimoxazole prophylaxis.

37 d to see if either increases the carriage of cotrimoxazole-resistant Streptococcus pneumoniae in Mala

38 For cotrimoxazole-treated children, the proportion colonized

39 Cotrimoxazole use is associated with benefits to WAZ but

40 In those underweight (WAZ < -2) at baseline, cotrimoxazole use was associated with a follow-up WAZ >/

41 ren who were stunted (HAZ < -2) at baseline, cotrimoxazole use was not associated with a follow-up HA

42 Cotrimoxazole use was not associated with a significant

43 ntly different between cotrimoxazole and non-cotrimoxazole users after 6 months of ART and remained s

44 an change in HAZ among cotrimoxazole and non-cotrimoxazole users did not differ significantly over th

45 sistance to ampicillin, chloramphenicol, and cotrimoxazole was 38.11%, with regional differences in s

46 ver injury due to antiretroviral therapy and cotrimoxazole was a frequent clinicopathological finding

47 In multivariate analysis, cotrimoxazole was associated with a cholestatic or ducto

48 Low-dose cotrimoxazole was not found to prevent Nocardia infectio

49 fections with trimethoprim/sulfamethoxazole (cotrimoxazole) was assessed to see if either increases t

50 Oral amoxicillin and cotrimoxazole were widely available at low cost in most

51 ing antiretroviral therapy (ART) discontinue cotrimoxazole when CD4 counts are >200 cells/muL.

52 herichia coli), only 24% were susceptible to cotrimoxazole, whereas 90% were susceptible to ciproflox